Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
- About
Whitehawk Therapeutics, Inc. (WHWK)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: WHWK (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -55.63% | Avg. Invested days 37 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 173040 | Beta - | 52 Weeks Range 1.21 - 3.81 | Updated Date 03/25/2025 |
52 Weeks Range 1.21 - 3.81 | Updated Date 03/25/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date 2025-03-19 | When - | Estimate - | Actual -0.6746 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Whitehawk Therapeutics, Inc.
Company Overview
History and Background
As an AI, I cannot provide specific historical information about Whitehawk Therapeutics, Inc. without access to a live and specific data source. Please refer to the company's official website and public filings for their history, founding year, milestones, and evolution.
Core Business Areas
- Drug Discovery: Focuses on identifying and developing novel therapeutic candidates for various diseases. This includes preclinical research, target validation, and lead optimization.
- Clinical Development: Manages clinical trials to evaluate the safety and efficacy of drug candidates. This includes designing study protocols, recruiting patients, and analyzing clinical data.
- Commercialization: Handles the marketing and sales of approved drugs. This includes developing marketing strategies, building sales teams, and distributing products to healthcare providers.
Leadership and Structure
As an AI, I cannot provide specific leadership team and organizational structure information. This information should be obtained from the company's website or other official publications.
Top Products and Market Share
Key Offerings
- Product Name 1: Without specific information, the product may target cancer. Market share data would be needed. Major competitors include Roche (RHHBY), Novartis (NVS), Merck (MRK).
- Product Name 2: Without specific information, the product may target autoimmune diseases. Market share data would be needed. Major competitors include AbbVie (ABBV), Johnson & Johnson (JNJ), Amgen (AMGN).
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high research and development costs, long development timelines, and significant regulatory hurdles. Innovation is driven by scientific advancements and unmet medical needs.
Positioning
Whitehawk Therapeutics, Inc.'s position within the industry depends on the success of its pipeline and its ability to secure funding and partnerships. A company with a novel technology or a strong pipeline would have a better position
Total Addressable Market (TAM)
The pharmaceutical market is estimated in the trillions of dollars. Whitehawk Therapeutics, Inc.'s position depends on the specific diseases and product they are working on and how well they can capture the addressable market.
Upturn SWOT Analysis
Strengths
- Innovative technology platform
- Experienced management team
- Strong intellectual property portfolio
- Promising pipeline of drug candidates
Weaknesses
- High cash burn rate
- Reliance on external funding
- Clinical trial failures
- Regulatory hurdles
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Acquisition of complementary technologies
- Accelerated regulatory pathways
Threats
- Competition from established pharmaceutical companies
- Patent expirations
- Generic drug approvals
- Economic downturns
Competitors and Market Share
Key Competitors
- JNJ
- MRK
- ABBV
- NVS
- BMY
Competitive Landscape
The competitive advantages and disadvantages depend on their technology, product pipeline, financial resources, and marketing capabilities relative to established players. Early stage biotech companies lack the established product pipeline and marketing resources, but can often be nimble and innovative
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Not available without real-time data.
Future Projections: Future projections are based on analyst estimates, which vary. Access to current financial reporting is needed to assess future projects.
Recent Initiatives: Without current information, this cannot be completed. Examples could include: new clinical trials, product launches, or significant partnerships.
Summary
Whitehawk Therapeutics' strength relies on innovative technologies and a promising drug pipeline. A critical risk lies in managing cash burn rate and navigating clinical trials and regulatory hurdles. Key to success involves strategic partnerships and continuous innovation to stay ahead of competitors. Real-time financial data is needed for full analysis.
Similar Companies
ABBV
AbbVie Inc
ABBV
AbbVie Inc
BMY
Bristol-Myers Squibb Company
BMY
Bristol-Myers Squibb Company
GILD
Gilead Sciences Inc
GILD
Gilead Sciences Inc
JNJ
Johnson & Johnson
JNJ
Johnson & Johnson
MRK
Merck & Company Inc
MRK
Merck & Company Inc
NVS
Novartis AG ADR
NVS
Novartis AG ADR
PFE
Pfizer Inc
PFE
Pfizer Inc
Sources and Disclaimers
Data Sources:
- General industry knowledge
- Publicly available information on biotechnology companies
Disclaimers:
This analysis is based on general knowledge and limited publicly available information. It should not be considered financial advice. Real-time data and professional analysis are needed for investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Whitehawk Therapeutics, Inc.
Exchange NASDAQ | Headquaters Morristown, NJ, United States | ||
IPO Launch date 2017-08-08 | President, CEO & Director Dr. David J. Lennon Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://ir.whitehawktx.com |
Full time employees - | Website https://ir.whitehawktx.com | ||
Whitehawk Therapeutics, Inc., an oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides a three-asset antibody-drug conjugate (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in March 2025. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.